Securus Technologies Sheds Light on the Disputed Patent no. 7,256,816

Integrity is one of the core values that Securus Technologies has strived to maintain in all its deals and operations in the corrections space. Therefore, when GTL released a press full of mistakes and discrepancies, Securus moved swiftly to paint the real picture to the corrections world by rectifying the inaccuracies.

 

Securus confirmed that it is moving for rehearing on U.S. patent no. 7,256,816 contrary to the GTL’s statements that the United States Patent Trial and Appeal Board (PTAB) had validated its claims. Securus also confirmed that the rehearing dates are yet to be announced. The firm also stated that it is not using GTL’s patented technologies in any of its video visitation platforms. Thus, GTL has no evidence or basis to file an infringement lawsuit against Securus.

 

Securus Technologies has built strong connections and partnerships with other major players in the corrections sector to improve the quality of solutions it delivers to its clients. It also signed a couple of license deals with GTL. However, Out of greed, GTL has been making several trips to courts and spending millions of dollars to engage in legal tussles with Securus over patents instead of renewing license agreements.

 

Securus Technologies

 

Securus Technologies has become a force in the corrections sector due to its revolutionary products and solutions that address challenges that corrections agencies face. It serves over one million detainees and more than 2,000 law enforcement and corrections facilities. The company develops products that aid corrections agencies to carry out biometric analysis, incident management, respond to emergencies, and investigation. It ensures incarcerated persons are communicating with their loved ones on a regular basis.

 

Acquisition of JPay

 

Therefore, the company closed a complete Stock Purchase Deal that saw it purchase JPay. On April 14, 2015. JPay is a technology firm known for unveiling electronic payments and a broad suite of educational and entertainment application in the corrections arena.

The Growth of Lime Crime

Doe Deere is an inspirational woman who is known as the founder as well as the current owner of Lime Crime, a makeup company that specializes in bright and beautiful colors for the cheeks, lips, as well as for the eyes that bring out the beautiful features in both men as well as women. Doe Deere created her successful business almost ten years ago and has attracted not only customers to the company, but also fans of her work that have become loyal to her internet brand over the years. The fans of Doe Deere have even named themselves the unicorns to add to the quirky style that Doe Deere has created for her company.

 

Doe Deere started Lime Crime as a side business to her clothing company, a company that also created beautiful as well as bright clothing for customers that wished to look good on the outside as well as fell good on the inside. Doe Deere is noted for her presence on many social media sites such as Instagram where Doe Deere has shown off her creativity and her talent with bright and bold colors that bring out the confidence of any man or woman that wears what she designs.

 

The name of Lime Crime is a name that was created by Doe Deere as a name that would stand out to customers that are looking to try a makeup product. The specific color of lime was chosen due to the fact that the color not only stands out, but is also the color that Doe Deere loves to work with the most. As a businesswoman, Doe Deere works hard to make sure that all of her customers are happy and to make sure that every single customer of hers has a say in what products are produced and are sold to the public.

 

In recent news, Doe Deere was interviewed by Galore magazine, a magazine that wanted to learn more about Doe Deere and about what has inspired her to expand her own internet-based business. During this interview, Doe Deere stated that she has always been a creative individual and has always believed that her job should be something that does not feel like a job.

Learn more:

Follow her on LinkedIn

Home

Oncotarget Offers A Disciplined Method of Publishing Scientific Papers

Since 2010, Oncotarget has been a well-known platform for the submission and publication of research papers and articles about oncology and related subjects. The research papers and articles are published weekly so that anything new of importance can be observed by the medical community at large as quickly as possible.

Oncotarget was founded in 2010, and the Editors-in-Chief are Mikhail Blagosklonny and Andrei V. Gudkov, both of the Roswell Park Cancer Institute, Buffalo, NY. Well-researched studies of the latest discoveries and procedures in the oncology field have a long history of saving lives when seemingly all hope has been lost.

Some of the fields in addition to oncology that are considered appropriate for submission, due to their relevance to the study of oncology include Endocrinology, Geotarget/Aging, Cardiology, Pharmacology, Metabolism, Neuropathologic/Neuroscience, Immunology/Microbiology and Cell and Mol Biology.

Researchers and authors submit their papers and manuscripts to the Editorial Board of Oncotarget. The editors on YouTube then thoroughly read and evaluate the paper, taking into consideration the merit of the paper, its uniqueness, its accuracy, the citations used as proofs, and the overall methods used to prove the main thesis.

Care is taken to research whether or not similar subjects have been written about and whether this paper is different enough in scope and proofs to warrant a new look. The complexity of oncology on scimagojr.com, particularly at the cellular level, leaves lots of room for expansion, yet there must be enough of a divergence to warrant a new look.

Editors work in pairs, and they must be expert in the subject in which each author submits. This peer review technique maintains the proper balance in expertise and accurate presentations, as the reviewers are well-versed on the subject matter.

Care is taken to that there is no other theme or distraction to cloud the intent and direction of the submitted item. For example, slander, opinion, political inferences, sexual orientation, racial or gender inferences, or any other distractive dialogue will not be permitted.

None of the material may be used by the editorial board for any personal use and all of the material contained in the submitted copy will be held as confidential, except with the author. This keeps the content pure and when published the medical community can be assured that the content is pristine and untainted.

Learn more about Oncotarget:
https://www.facebook.com/Oncotarget/
https://www.dovepress.com/oncotargets-and-therapy-journal